Combination nivo/ipi does not significantly improve OS compared with gemcitabine plus carboplatin in patients with previously untreated unresectable or metastatic urothelial carcinoma, according to final results from the CheckMate-901 trial (Abstract 4500).

Data from two phase 3 studies demonstrate the efficacy of romiplostim and Carica papaya leaf extract for the treatment of chemotherapy-induced thrombocytopenia, for which there are currently no U.S. Food and Drug Administration–approved therapies (Abstract 12007 and Abstract 12008).

HER3-DXd significantly improves progression-free survival when compared with platinum-based chemotherapy in patients with treatment-resistant EGFR-mutated non–small cell lung cancer, according to results of the phase 3 HERTHENA-Lung02 trial (Abstract 8506).

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the VERIFY trial—LBA3 from the 2025 Plenary Session—which evaluated treatment with the hepcidin mimetic rusfertide in patients with polycythemia vera.

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the NIVOPOSTOP trial—LBA2 from the 2025 Plenary Session—which assessed adjuvant nivolumab added to chemoradiotherapy in patients with resected head and neck squamous cell carcinoma.

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the ATOMIC trial—LBA1 from the 2025 Plenary Session—which assessed the efficacy and safety of atezolizumab combined with standard chemotherapy in patients with stage III colon cancer with deficient DNA mismatch repair.

Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer.